Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission
Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe
Hepatitis C genotype 3 progresses faster than genotype 1 and is one of the most difficult-to-treat genotypes
And it works!
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission
Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe
Hepatitis C genotype 3 progresses faster than genotype 1 and is one of the most difficult-to-treat genotypes
http://hepatitiscnewdrugs.blogspot.com/2015/09/hepatitis-c-genotype-3-updated-label.html